View in EDS

Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.

Saved in:
Bibliographic Details
Title: Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.
Authors: Oh DY; Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: ohdoyoun@snu.ac.kr., He AR; Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA., Qin S; Cancer Center of Nanjing, Jinling Hospital, Nanjing, China., Chen LT; Kaohsiung Medical University Hospital and Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan; National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan., Okusaka T; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan., Kim JW; Medical Oncology, Seoul National University Bundang Hospital, Seoul, Republic of Korea., Suksombooncharoen T; Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand., Lee MA; Seoul St. Mary's Hospital, College of Medicine, Cancer Research Institute, The Catholic University of Korea, Seoul, Republic of Korea., Kitano M; Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan., Burris HA; Drug Development Department, Sarah Cannon Research Institute, Nashville, Tennessee, USA., Bouattour M; Medical Oncology, AP-HP Hôpital Beaujon, Paris, France., Tanasanvimon S; Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand., Zaucha R; Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland., Avallone A; Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, Italy., Cundom J; Medical Oncology, Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina., Kuzko A; Oncology R&D, AstraZeneca, Warsaw, Poland., Wang J; Oncology R&D, AstraZeneca, New York, New York, USA., Xynos I; Oncology R&D, AstraZeneca, Cambridge, UK., Vogel A; Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Medical School Hannover, Hannover, Germany., Valle JW; Research, Cholangiocarcinoma Foundation, Herriman, Utah, USA; Division of Cancer Sciences, University of Manchester, Manchester, UK.
Source: Journal of hepatology [J Hepatol] 2025 Nov; Vol. 83 (5), pp. 1092-1101. Date of Electronic Publication: 2025 May 15.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8503886 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0641 (Electronic) Linking ISSN: 01688278 NLM ISO Abbreviation: J Hepatol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40381735
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Oh+DY%22">Oh DY</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: ohdoyoun@snu.ac.kr.<br /><searchLink fieldCode="AU" term="%22He+AR%22">He AR</searchLink>; Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.<br /><searchLink fieldCode="AU" term="%22Qin+S%22">Qin S</searchLink>; Cancer Center of Nanjing, Jinling Hospital, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Chen+LT%22">Chen LT</searchLink>; Kaohsiung Medical University Hospital and Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan; National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan.<br /><searchLink fieldCode="AU" term="%22Okusaka+T%22">Okusaka T</searchLink>; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Kim+JW%22">Kim JW</searchLink>; Medical Oncology, Seoul National University Bundang Hospital, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Suksombooncharoen+T%22">Suksombooncharoen T</searchLink>; Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.<br /><searchLink fieldCode="AU" term="%22Lee+MA%22">Lee MA</searchLink>; Seoul St. Mary's Hospital, College of Medicine, Cancer Research Institute, The Catholic University of Korea, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kitano+M%22">Kitano M</searchLink>; Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.<br /><searchLink fieldCode="AU" term="%22Burris+HA%22">Burris HA</searchLink>; Drug Development Department, Sarah Cannon Research Institute, Nashville, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Bouattour+M%22">Bouattour M</searchLink>; Medical Oncology, AP-HP Hôpital Beaujon, Paris, France.<br /><searchLink fieldCode="AU" term="%22Tanasanvimon+S%22">Tanasanvimon S</searchLink>; Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.<br /><searchLink fieldCode="AU" term="%22Zaucha+R%22">Zaucha R</searchLink>; Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.<br /><searchLink fieldCode="AU" term="%22Avallone+A%22">Avallone A</searchLink>; Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, Italy.<br /><searchLink fieldCode="AU" term="%22Cundom+J%22">Cundom J</searchLink>; Medical Oncology, Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina.<br /><searchLink fieldCode="AU" term="%22Kuzko+A%22">Kuzko A</searchLink>; Oncology R&D, AstraZeneca, Warsaw, Poland.<br /><searchLink fieldCode="AU" term="%22Wang+J%22">Wang J</searchLink>; Oncology R&D, AstraZeneca, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Xynos+I%22">Xynos I</searchLink>; Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Vogel+A%22">Vogel A</searchLink>; Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Medical School Hannover, Hannover, Germany.<br /><searchLink fieldCode="AU" term="%22Valle+JW%22">Valle JW</searchLink>; Research, Cholangiocarcinoma Foundation, Herriman, Utah, USA; Division of Cancer Sciences, University of Manchester, Manchester, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228503886%22">Journal of hepatology</searchLink> [J Hepatol] 2025 Nov; Vol. 83 (5), pp. 1092-1101. <i>Date of Electronic Publication: </i>2025 May 15.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8503886 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1600-0641 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201688278%22">01688278 </searchLink><i>NLM ISO Abbreviation: </i>J Hepatol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40381735
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jhep.2025.05.003
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1092
    Titles:
      – TitleFull: Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Oh DY
      – PersonEntity:
          Name:
            NameFull: He AR
      – PersonEntity:
          Name:
            NameFull: Qin S
      – PersonEntity:
          Name:
            NameFull: Chen LT
      – PersonEntity:
          Name:
            NameFull: Okusaka T
      – PersonEntity:
          Name:
            NameFull: Kim JW
      – PersonEntity:
          Name:
            NameFull: Suksombooncharoen T
      – PersonEntity:
          Name:
            NameFull: Lee MA
      – PersonEntity:
          Name:
            NameFull: Kitano M
      – PersonEntity:
          Name:
            NameFull: Burris HA
      – PersonEntity:
          Name:
            NameFull: Bouattour M
      – PersonEntity:
          Name:
            NameFull: Tanasanvimon S
      – PersonEntity:
          Name:
            NameFull: Zaucha R
      – PersonEntity:
          Name:
            NameFull: Avallone A
      – PersonEntity:
          Name:
            NameFull: Cundom J
      – PersonEntity:
          Name:
            NameFull: Kuzko A
      – PersonEntity:
          Name:
            NameFull: Wang J
      – PersonEntity:
          Name:
            NameFull: Xynos I
      – PersonEntity:
          Name:
            NameFull: Vogel A
      – PersonEntity:
          Name:
            NameFull: Valle JW
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2025 Nov
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1600-0641
          Numbering:
            – Type: volume
              Value: 83
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Journal of hepatology
              Type: main
ResultId 1